Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.
8 May 2025 Date | | - Cons. EPS | - EPS |
22 Aug 2024 Date | | - Cons. EPS | - EPS |
9 May 2024 Date | | - Cons. EPS | - EPS |
8 May 2025 Date | | - Cons. EPS | - EPS |
22 Aug 2024 Date | | - Cons. EPS | - EPS |
9 May 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Dr. Dajun Yang M.D., Ph.D. CEO | OTC PINK Exchange | KYG0519B1023 ISIN |
CN Country | 567 Employees | - Last Dividend | - Last Split | - IPO Date |
Ascentage Pharma Group International is a prominent clinical-stage biotechnology company based in Suzhou, China, dedicated to the development of innovative therapies for a variety of critical health issues, including cancers, chronic hepatitis B virus (HBV) infections, and age-related diseases. Since its establishment in 2009, Ascentage Pharma has embarked on a mission to address unmet medical needs through pioneering research and development efforts. Leveraging its scientific expertise and collaboration with leading biotechnology and pharmaceutical companies, as well as research institutions, Ascentage Pharma is at the forefront of discovering and developing significant medical breakthroughs. The company's operations also extend to medical research and development, clinical trial operation, venture capital investment, rental services, and promotion of science and technology, positioning it as a versatile player in the biotech industry.
HQP1351: HQP1351 stands as Ascentage Pharma's primary product candidate, designed as a BCR-ABL inhibitor specifically targeting BCR-ABL1 mutants, including those resistant to treatment due to the T315I mutation. This innovation signifies a promising therapeutic option for patients battling certain types of cancer.
APG-2575: This compound is an oral Bcl-2 selective inhibitor intended for treating hematologic malignancies and solid tumors. By specifically targeting the Bcl-2 protein, APG-2575 aims to induce apoptosis in cancer cells, thereby contributing to cancer treatment regimens.
APG-115: APG-115 operates as a potent oral small molecule inhibitor that disrupts MDM2-p53 protein-protein interactions. This mechanism is vital for the treatment of solid tumors and hematological malignancies, providing a new approach to activating p53-mediated tumor suppression.
APG-1252: This small molecule drug is designed to combat cancer through the dual inhibition of Bcl-2 and Bcl-xL proteins, crucial for restoring apoptosis in malignant cells. APG-1252 targets a range of cancers, including small-cell and non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma.
APG-1387: As a small-molecule inhibitor of apoptosis proteins, APG-1387 offers therapeutic potential for patients with advanced solid tumors and chronic HBV infection. Its mechanism involves impacting the apoptosis pathways, which play a critical role in cancer development and viral infections.
APG-2449: An oral inhibitor that targets FAK, ROS1, and ALK kinases, APG-2449 is developed to interfere with crucial signaling pathways in cancer cells. This compound represents an innovative approach to halting the growth and spread of cancer.
APG-5918: This orally available compound serves as a selective inhibitor of embryonic ectoderm development, a pathway implicated in cancer progression. APG-5918's unique targeting mechanism offers new possibilities for treating various cancers.
APG-265: By degrading the MDM2 protein, APG-265 offers a novel strategy to reactivate the p53 tumor suppressor pathway. This approach holds promise for effectively tackling malignancies that have evaded other forms of treatment.
UBX1967/1325: Functioning as Bcl-2 inhibitors, UBX1967 and UBX1325 are part of Ascentage Pharma's arsenal against cancer, aiming to restore the apoptotic process in cancerous cells and thereby provide a therapeutic advantage in the fight against this debilitating disease.
In addition, Ascentage Pharma Group International's involvement in medical research and development, clinical development, clinical trial operation, venture capital investment, rental services, and science and technology promotion services showcases its comprehensive range of capabilities to advance medical science and healthcare solutions.